Latest Orphan drugs Stories
A combination of nab-paclitaxel and carboplatin for the treatment of non-small cell lung cancer may be a promising option for patients ineligible for treatment with bevacizumab.
Treatment with three relatively new "targeted" cancer drugs has been linked to a slightly elevated chance of fatal side effects.
BioPlus Specialty Pharmacy selected as one of the limited number of specialty pharmacies with access to this advanced renal cell carcinoma second line therapy. Altamonte